In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DexCom: The Beauty Of Open Architecture

Executive Summary

Today the fight for the continuous glucose monitoring market isn’t so much about a large company and a mid-sized one battling for market share as about acceptance of the entire category of CGM, which remains low after more than a decade. DexCom believes that CGM should be a first-line blood glucose management tool to help diabetes patients keep their blood glucose levels within a healthy range, and now with the launch of a stellar fourth-generation product, the company is closer than ever to realizing that goal.

Advertisement

Related Content

Q&A: ‘Rock Star’ Cardiologist Eric Topol Extols Virtues Of Digital Health
Artificial Pancreas Guidance Allows For More Flexibility In Trial Design
Device, Pharma Execs Explore mHealth Ecosystem At ATA Fall Forum
Tight Glycemic Control: Critical Care’s Balancing Act
FDA Wants To See New, Improved Hospital Continuous Glucose Monitors
One Study Down, Three To Go On Animas’ First-Gen Artificial Pancreas Project
Emerging Diabetes Technology Driven By Patient Demands
Continuous Glucose Monitoring: A Case Study for Commercializing Products In The Era of Patient-Driven Health Care
Edwards Lifesciences and Dexcom Join Forces in New Critical Care Growth Market
Continuous Glucose Monitoring: A Revolution Powered by DexCom

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004009

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel